Enliven Therapeutics, Inc.
News
Enliven Therapeutics, Inc. Forecasted to Post Q3 2024 Earnings of ($0.46) Per Share (NASDAQ:ELVN)
Ticker Report Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - HC Wainwright issued their Q3 2024 EPS estimates for Enliven Therapeutics in a research report issued to clients and investors on Monday...\n more…
Research Analysts Offer Predictions for Enliven Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ELVN)
Zolmax Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Enliven Therapeutics in a note issued to investors on Monday...\n more…
HC Wainwright Weighs in on Enliven Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ELVN)
Ticker Report Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Enliven Therapeutics in a report released on Monday...\n more…
Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at HC Wainwright
Ticker Report HC Wainwright assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN - Free Report) in a research report report published on Monday morning, MarketBeat.com reports. The brokerage issued a...\n more…
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
Zacks Investment Research Enliven Therapeutics, Inc. (ELVN) closed the last trading session at $22.20, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets...\n more…